Linda Burkly, Executive Vice President and Chief Scientific Officer at Editas Medicine, Inc. (), sold 4,928 shares of the company’s common stock on July 28, 2026. The shares were sold at a price of $2.67 per share, totaling approximately $13,157.
Jonathan Sheena, a director and co-founder at Natera, Inc. (), sold shares totaling $123,548 over two separate transactions in late July 2026. The sales occurred at prices ranging from $254.0696 to $260.4908. On July 27, 2026, Sheena disposed of 288 shares of common
LIVINGSTON, N.J. – Brannin McBee, Chief Development Officer at CoreWeave, Inc. (), reported the sale of 237,000 shares of the company’s Class A Common Stock on July 27, 2026. The transactions totaled $16,836,129, with shares sold at prices ranging
Derek J. Maetzold, President and Chief Executive Officer and a Director of Castle Biosciences Inc. (), sold shares of the company’s common stock totaling $237,682 on July 27, 2026. The sales were executed at prices ranging from $23.85 to $25.11
Sarah Tolman, Executive Vice President and Chief Banking Officer at First Bancorp, Inc. (), sold 5,200 shares of common stock on July 28, 2026. The transaction totaled $183,144, with shares sold at a price of $35.22 each. The sale came as
Theodor Werner Freye, a director at Valmont Industries (), sold 800 shares of the company’s common stock on July 27, 2026. The transaction totaled $396,000. The shares were sold at a price of $495.00 per share. Following this sale, Mr.
Snehal Patel, CEO and CFO of Greenwich LifeSciences, Inc. (), recently purchased company stock valued at $20,430. The transaction occurred on July 27, 2026. Mr. Patel acquired 1,500 shares of Greenwich LifeSciences common stock at a price of $13.62 per share.
Sumeet Puri, Chief Accounting Officer at Eos Energy Enterprises, Inc. (), recently executed transactions involving the company’s common stock, according to a recent filing. On July 28, 2026, Mr. Puri disposed of 29,167 shares of Eos Energy Enterprises
Nathan Kroeker, Chief Commercial Officer at Eos Energy Enterprises, Inc. (), sold 110,417 shares of the company’s common stock on July 28, 2026, for a total value of $371,001. The shares were sold at prices ranging from $3.23 to $3.48 per
RA Capital Management, L.P., a reporting person identified as both a director and a 10% owner of Artiva Biotherapeutics, Inc. (), acquired 41,319 shares of the company’s common stock on July 24, 2026. The total value of these
